The study showed that after injecting CCR2 antagonist into the abdominal cavity of mice with in-situ liver cancer model, the number of TAMs in liver cancer tumour was significantly reduced, while CD8+ T cells were significantly increased, which significantly inhibited tumour growth [75, 76]. This evidence concerns the gene CD8A and liver cancer.